Loading…
mRNA as gene therapeutic: How to control protein expression
For many years, it was generally accepted that mRNA is too unstable to be efficiently used for gene therapy purposes. In the last decade, however, several research groups faced this challenge and not only proved the feasibility of mRNA‐mediated transfection with surprising results regarding transfec...
Saved in:
Published in: | Journal of controlled release 2011-03, Vol.150 (3), p.238-247 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c516t-637ec7fb2e71995b2dde124be1bdce0701fd893e5c4c04c03a47558c43436bf73 |
---|---|
cites | cdi_FETCH-LOGICAL-c516t-637ec7fb2e71995b2dde124be1bdce0701fd893e5c4c04c03a47558c43436bf73 |
container_end_page | 247 |
container_issue | 3 |
container_start_page | 238 |
container_title | Journal of controlled release |
container_volume | 150 |
creator | Tavernier, Geertrui Andries, Oliwia Demeester, Jo Sanders, Niek N. De Smedt, Stefaan C. Rejman, Joanna |
description | For many years, it was generally accepted that mRNA is too unstable to be efficiently used for gene therapy purposes. In the last decade, however, several research groups faced this challenge and not only proved the feasibility of mRNA‐mediated transfection with surprising results regarding transfection efficiency and duration of protein expression, but also were able to demonstrate major advantages over the use of pDNA. These advantages will be the first issue discussed in this review, which first of all addresses the notions that mRNA does not need to cross the nuclear barrier to exert its biological activity and in addition lacks CpG motifs, which reduces its immunogenicity. Secondly, it provides insight in the (in)stability of the mRNA molecule, in how mRNA can be modified to increase its half‐life and in the necessities of exogenously produced mRNA to be successfully used in transfection protocols. Furthermore, this review gives an in‐depth overview of the different techniques and vehicles for intracellular mRNA delivery exploited by us and other groups, comprising electroporation, gene gun injection, lipo‐ and polyplexes. Finally, it covers recent literature describing specific applications for mRNA based gene delivery, showing that until now most attention has been paid to vaccination strategies. This review offers a comprehensive overview of current knowledge of the major theoretical as well as practical aspects of mRNA-mediated transfection, showing both its possibilities and its pitfalls and should therefore be useful for a diverse scientific audience.
[Display omitted] |
doi_str_mv | 10.1016/j.jconrel.2010.10.020 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_876233654</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365910008308</els_id><sourcerecordid>876233654</sourcerecordid><originalsourceid>FETCH-LOGICAL-c516t-637ec7fb2e71995b2dde124be1bdce0701fd893e5c4c04c03a47558c43436bf73</originalsourceid><addsrcrecordid>eNqFkE1P3DAQhi1UBNttfwKQC-opy_g7aQ8IoRaQEJWgnC3HmYBX2XhrZ9vy7_F2FzgiWbI0embmnYeQAwozClSdzGdzF4aI_YzB_9oMGOyQCa00L0Vdyw9kkrmq5ErW--RjSnMAkFzoPbLPoNYgVD0h3xa3N2eFTcUDDliMjxjtElejd1-Ly_C3GEORt4wx9MUyhhH9UOC_ZcSUfBg-kd3O9gk_b_8puf_x_df5ZXn98-Lq_Oy6dJKqsVRco9Ndw1DTnKthbYuUiQZp0zoEDbRrq5qjdMJBftwKLWXlBBdcNZ3mU_JlMzdH-L3CNJqFTw773g4YVslUWjGezxTvk4oLphWsZ8oN6WJIKWJnltEvbHwyFMxasJmbrWCzFrwuZ8G573C7YdUssH3tejGageMtYJOzfRft4Hx64wRllahp5o42XGeDsQ8xM_d3eZMEoBVV-aIpOd0QmN3-8RhNch4Hh62P6EbTBv9O2GfroqOl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>863427607</pqid></control><display><type>article</type><title>mRNA as gene therapeutic: How to control protein expression</title><source>Elsevier</source><creator>Tavernier, Geertrui ; Andries, Oliwia ; Demeester, Jo ; Sanders, Niek N. ; De Smedt, Stefaan C. ; Rejman, Joanna</creator><creatorcontrib>Tavernier, Geertrui ; Andries, Oliwia ; Demeester, Jo ; Sanders, Niek N. ; De Smedt, Stefaan C. ; Rejman, Joanna</creatorcontrib><description>For many years, it was generally accepted that mRNA is too unstable to be efficiently used for gene therapy purposes. In the last decade, however, several research groups faced this challenge and not only proved the feasibility of mRNA‐mediated transfection with surprising results regarding transfection efficiency and duration of protein expression, but also were able to demonstrate major advantages over the use of pDNA. These advantages will be the first issue discussed in this review, which first of all addresses the notions that mRNA does not need to cross the nuclear barrier to exert its biological activity and in addition lacks CpG motifs, which reduces its immunogenicity. Secondly, it provides insight in the (in)stability of the mRNA molecule, in how mRNA can be modified to increase its half‐life and in the necessities of exogenously produced mRNA to be successfully used in transfection protocols. Furthermore, this review gives an in‐depth overview of the different techniques and vehicles for intracellular mRNA delivery exploited by us and other groups, comprising electroporation, gene gun injection, lipo‐ and polyplexes. Finally, it covers recent literature describing specific applications for mRNA based gene delivery, showing that until now most attention has been paid to vaccination strategies. This review offers a comprehensive overview of current knowledge of the major theoretical as well as practical aspects of mRNA-mediated transfection, showing both its possibilities and its pitfalls and should therefore be useful for a diverse scientific audience.
[Display omitted]</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2010.10.020</identifier><identifier>PMID: 20970469</identifier><identifier>CODEN: JCREEC</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Animals ; bioactive properties ; Biological and medical sciences ; Controlled release ; CpG islands ; Electroporation ; Gene therapy ; Gene transfer ; General pharmacology ; genes ; half life ; Humans ; immune response ; Immunogenicity ; Immunotherapy - methods ; Lipoplexes ; Medical sciences ; messenger RNA ; mRNA ; mRNA delivery ; mRNA vaccines ; Neoplasms - therapy ; Nuclear barrier ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Poly(A)tail ; Polyplexes ; protein synthesis ; Reviews ; RNA, Messenger - genetics ; RNA, Messenger - therapeutic use ; Transfection ; Transfection - methods ; Vaccination</subject><ispartof>Journal of controlled release, 2011-03, Vol.150 (3), p.238-247</ispartof><rights>2010 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c516t-637ec7fb2e71995b2dde124be1bdce0701fd893e5c4c04c03a47558c43436bf73</citedby><cites>FETCH-LOGICAL-c516t-637ec7fb2e71995b2dde124be1bdce0701fd893e5c4c04c03a47558c43436bf73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24128491$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20970469$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tavernier, Geertrui</creatorcontrib><creatorcontrib>Andries, Oliwia</creatorcontrib><creatorcontrib>Demeester, Jo</creatorcontrib><creatorcontrib>Sanders, Niek N.</creatorcontrib><creatorcontrib>De Smedt, Stefaan C.</creatorcontrib><creatorcontrib>Rejman, Joanna</creatorcontrib><title>mRNA as gene therapeutic: How to control protein expression</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>For many years, it was generally accepted that mRNA is too unstable to be efficiently used for gene therapy purposes. In the last decade, however, several research groups faced this challenge and not only proved the feasibility of mRNA‐mediated transfection with surprising results regarding transfection efficiency and duration of protein expression, but also were able to demonstrate major advantages over the use of pDNA. These advantages will be the first issue discussed in this review, which first of all addresses the notions that mRNA does not need to cross the nuclear barrier to exert its biological activity and in addition lacks CpG motifs, which reduces its immunogenicity. Secondly, it provides insight in the (in)stability of the mRNA molecule, in how mRNA can be modified to increase its half‐life and in the necessities of exogenously produced mRNA to be successfully used in transfection protocols. Furthermore, this review gives an in‐depth overview of the different techniques and vehicles for intracellular mRNA delivery exploited by us and other groups, comprising electroporation, gene gun injection, lipo‐ and polyplexes. Finally, it covers recent literature describing specific applications for mRNA based gene delivery, showing that until now most attention has been paid to vaccination strategies. This review offers a comprehensive overview of current knowledge of the major theoretical as well as practical aspects of mRNA-mediated transfection, showing both its possibilities and its pitfalls and should therefore be useful for a diverse scientific audience.
[Display omitted]</description><subject>Animals</subject><subject>bioactive properties</subject><subject>Biological and medical sciences</subject><subject>Controlled release</subject><subject>CpG islands</subject><subject>Electroporation</subject><subject>Gene therapy</subject><subject>Gene transfer</subject><subject>General pharmacology</subject><subject>genes</subject><subject>half life</subject><subject>Humans</subject><subject>immune response</subject><subject>Immunogenicity</subject><subject>Immunotherapy - methods</subject><subject>Lipoplexes</subject><subject>Medical sciences</subject><subject>messenger RNA</subject><subject>mRNA</subject><subject>mRNA delivery</subject><subject>mRNA vaccines</subject><subject>Neoplasms - therapy</subject><subject>Nuclear barrier</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Poly(A)tail</subject><subject>Polyplexes</subject><subject>protein synthesis</subject><subject>Reviews</subject><subject>RNA, Messenger - genetics</subject><subject>RNA, Messenger - therapeutic use</subject><subject>Transfection</subject><subject>Transfection - methods</subject><subject>Vaccination</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqFkE1P3DAQhi1UBNttfwKQC-opy_g7aQ8IoRaQEJWgnC3HmYBX2XhrZ9vy7_F2FzgiWbI0embmnYeQAwozClSdzGdzF4aI_YzB_9oMGOyQCa00L0Vdyw9kkrmq5ErW--RjSnMAkFzoPbLPoNYgVD0h3xa3N2eFTcUDDliMjxjtElejd1-Ly_C3GEORt4wx9MUyhhH9UOC_ZcSUfBg-kd3O9gk_b_8puf_x_df5ZXn98-Lq_Oy6dJKqsVRco9Ndw1DTnKthbYuUiQZp0zoEDbRrq5qjdMJBftwKLWXlBBdcNZ3mU_JlMzdH-L3CNJqFTw773g4YVslUWjGezxTvk4oLphWsZ8oN6WJIKWJnltEvbHwyFMxasJmbrWCzFrwuZ8G573C7YdUssH3tejGageMtYJOzfRft4Hx64wRllahp5o42XGeDsQ8xM_d3eZMEoBVV-aIpOd0QmN3-8RhNch4Hh62P6EbTBv9O2GfroqOl</recordid><startdate>20110330</startdate><enddate>20110330</enddate><creator>Tavernier, Geertrui</creator><creator>Andries, Oliwia</creator><creator>Demeester, Jo</creator><creator>Sanders, Niek N.</creator><creator>De Smedt, Stefaan C.</creator><creator>Rejman, Joanna</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20110330</creationdate><title>mRNA as gene therapeutic: How to control protein expression</title><author>Tavernier, Geertrui ; Andries, Oliwia ; Demeester, Jo ; Sanders, Niek N. ; De Smedt, Stefaan C. ; Rejman, Joanna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c516t-637ec7fb2e71995b2dde124be1bdce0701fd893e5c4c04c03a47558c43436bf73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>bioactive properties</topic><topic>Biological and medical sciences</topic><topic>Controlled release</topic><topic>CpG islands</topic><topic>Electroporation</topic><topic>Gene therapy</topic><topic>Gene transfer</topic><topic>General pharmacology</topic><topic>genes</topic><topic>half life</topic><topic>Humans</topic><topic>immune response</topic><topic>Immunogenicity</topic><topic>Immunotherapy - methods</topic><topic>Lipoplexes</topic><topic>Medical sciences</topic><topic>messenger RNA</topic><topic>mRNA</topic><topic>mRNA delivery</topic><topic>mRNA vaccines</topic><topic>Neoplasms - therapy</topic><topic>Nuclear barrier</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Poly(A)tail</topic><topic>Polyplexes</topic><topic>protein synthesis</topic><topic>Reviews</topic><topic>RNA, Messenger - genetics</topic><topic>RNA, Messenger - therapeutic use</topic><topic>Transfection</topic><topic>Transfection - methods</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tavernier, Geertrui</creatorcontrib><creatorcontrib>Andries, Oliwia</creatorcontrib><creatorcontrib>Demeester, Jo</creatorcontrib><creatorcontrib>Sanders, Niek N.</creatorcontrib><creatorcontrib>De Smedt, Stefaan C.</creatorcontrib><creatorcontrib>Rejman, Joanna</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tavernier, Geertrui</au><au>Andries, Oliwia</au><au>Demeester, Jo</au><au>Sanders, Niek N.</au><au>De Smedt, Stefaan C.</au><au>Rejman, Joanna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>mRNA as gene therapeutic: How to control protein expression</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2011-03-30</date><risdate>2011</risdate><volume>150</volume><issue>3</issue><spage>238</spage><epage>247</epage><pages>238-247</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><coden>JCREEC</coden><abstract>For many years, it was generally accepted that mRNA is too unstable to be efficiently used for gene therapy purposes. In the last decade, however, several research groups faced this challenge and not only proved the feasibility of mRNA‐mediated transfection with surprising results regarding transfection efficiency and duration of protein expression, but also were able to demonstrate major advantages over the use of pDNA. These advantages will be the first issue discussed in this review, which first of all addresses the notions that mRNA does not need to cross the nuclear barrier to exert its biological activity and in addition lacks CpG motifs, which reduces its immunogenicity. Secondly, it provides insight in the (in)stability of the mRNA molecule, in how mRNA can be modified to increase its half‐life and in the necessities of exogenously produced mRNA to be successfully used in transfection protocols. Furthermore, this review gives an in‐depth overview of the different techniques and vehicles for intracellular mRNA delivery exploited by us and other groups, comprising electroporation, gene gun injection, lipo‐ and polyplexes. Finally, it covers recent literature describing specific applications for mRNA based gene delivery, showing that until now most attention has been paid to vaccination strategies. This review offers a comprehensive overview of current knowledge of the major theoretical as well as practical aspects of mRNA-mediated transfection, showing both its possibilities and its pitfalls and should therefore be useful for a diverse scientific audience.
[Display omitted]</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>20970469</pmid><doi>10.1016/j.jconrel.2010.10.020</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0168-3659 |
ispartof | Journal of controlled release, 2011-03, Vol.150 (3), p.238-247 |
issn | 0168-3659 1873-4995 |
language | eng |
recordid | cdi_proquest_miscellaneous_876233654 |
source | Elsevier |
subjects | Animals bioactive properties Biological and medical sciences Controlled release CpG islands Electroporation Gene therapy Gene transfer General pharmacology genes half life Humans immune response Immunogenicity Immunotherapy - methods Lipoplexes Medical sciences messenger RNA mRNA mRNA delivery mRNA vaccines Neoplasms - therapy Nuclear barrier Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Poly(A)tail Polyplexes protein synthesis Reviews RNA, Messenger - genetics RNA, Messenger - therapeutic use Transfection Transfection - methods Vaccination |
title | mRNA as gene therapeutic: How to control protein expression |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T19%3A19%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=mRNA%20as%20gene%20therapeutic:%20How%20to%20control%20protein%20expression&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Tavernier,%20Geertrui&rft.date=2011-03-30&rft.volume=150&rft.issue=3&rft.spage=238&rft.epage=247&rft.pages=238-247&rft.issn=0168-3659&rft.eissn=1873-4995&rft.coden=JCREEC&rft_id=info:doi/10.1016/j.jconrel.2010.10.020&rft_dat=%3Cproquest_cross%3E876233654%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c516t-637ec7fb2e71995b2dde124be1bdce0701fd893e5c4c04c03a47558c43436bf73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=863427607&rft_id=info:pmid/20970469&rfr_iscdi=true |